Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Diabetes Metab J. 2012 Oct;36(5):364-70. doi: 10.4093/dmj.2012.36.5.364. Epub 2012 Oct 18.
While many studies have shown the good efficacy and safety of exenatide in patients with diabetes, limited information is available about exenatide in clinical practice in Korean populations. Therefore, this retrospective cohort study was designed to analyze the effects of exenatide on blood glucose level and body weight in Korean patients with type 2 diabetes mellitus.
We reviewed the records of the patients with diabetes who visited Seoul St. Mary's Hospital and for whom exenatide was prescribed from June 2009 to October 2011. After excluding subjects based on their race/ethnicity, medical history, whether or not they changed more than 2 kinds of oral hypoglycemic agents with exenatide treatment, loss to follow-up, or whether they stopped exenatide therapy within 6 months, a total of 52 subjects were included in the final analysis.
The mean glycated hemoglobin (HbA1c) level and weight remarkably decreased from 8.5±1.7% to 6.7±1.0% (P<0.001) and from 82.3±15.8 kg to 78.6±16.3 kg (P<0.001), respectively. The multiple regression analysis indicated that the reduction in HbA1c level was significantly associated with a shorter duration of diabetes, a higher baseline HbA1c level, and greater weight reduction, whereas weight loss had no significant correlation with other factors. No severe adverse events were observed.
These results suggest that a 6-month exenatide injection therapy significantly improved patients' HbA1c levels and body weights without causing serious adverse effects in Korean patients with type 2 diabetes.
虽然许多研究表明艾塞那肽在糖尿病患者中的疗效和安全性良好，但关于其在韩国人群中的临床应用信息有限。因此，本回顾性队列研究旨在分析艾塞那肽对韩国 2 型糖尿病患者血糖水平和体重的影响。
我们回顾了 2009 年 6 月至 2011 年 10 月期间在首尔圣玛丽医院就诊并接受艾塞那肽治疗的糖尿病患者的病历。根据种族/民族、既往病史、是否在艾塞那肽治疗期间改用超过 2 种口服降糖药、失访或在 6 个月内停止艾塞那肽治疗等因素排除患者后，共有 52 例患者最终纳入了本研究。
糖化血红蛋白（HbA1c）水平和体重分别从 8.5±1.7%显著下降至 6.7±1.0%（P<0.001）和从 82.3±15.8kg 显著下降至 78.6±16.3kg（P<0.001）。多因素回归分析表明，HbA1c 水平的降低与糖尿病病程较短、基线 HbA1c 水平较高和体重减轻较大有关，而体重减轻与其他因素无显著相关性。未观察到严重不良事件。
这些结果表明，在韩国 2 型糖尿病患者中，6 个月的艾塞那肽注射治疗可显著改善患者的 HbA1c 水平和体重，且无严重不良事件发生。
